Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
04/07/2023 - 08:24 AM
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers.
Highlights of the peer-reviewed publication include:
In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status. A similar trend was observed in the pMMR population (n=110) that does not currently qualify for ICI therapy in mCRC. In the pMMR group treated with ICI addition to chemo (N=69), patients that had a very high DetermaIO had a significantly improved progression-free survival (HR=0.19 95% CI: 0.09 - 0.40). Overlap between DetermaIO positive, dMMR, and TMB is limited, demonstrating DetermaIO identifies a unique subset of patients not identified by these biomarkers. The authors conclude, “Our study demonstrates that the gene expression profiling through the DetermaIO of mCRC would mark a fundamental paradigm shift in the characterization of tumor immune microenvironment of mCRC, by providing the opportunity to identify an immune-enriched tumor microenvironment among pMMR tumors that do not currently qualify for ICI therapy.”
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy.
DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation
Investor Contact jarno@oncocyte.com
Oncocyte Corporation
NASDAQ:OCX
OCX Rankings
#5367 Ranked by Stock Gains
OCX Stock Data
Industry
In-Vitro Diagnostic Substance Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, In-Vitro Diagnostic Substance Manufacturing
Country
US
City
Irvine
About OCX
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
